1-6 of 6
Nancy L. Bartlett
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma

Jennifer A. Foltz, Brian T. Hess, Veronika Bachanova, Nancy L. Bartlett, Melissa M. Berrien-Elliott, Ethan McClain, Michelle Becker-Hapak, Mark Foster, Timothy Schappe, Brad Kahl, Neha Mehta-Shah, Amanda F. Cashen, Nancy D. Marin, Kristen McDaniels, Chaz Moreno, Matthew Mosior, Feng Gao, Obi L. Griffith, Malachi Griffith, Julia A. Wagner, Narendranath Epperla, Amy D. Rock, John Lee, Allegra A. Petti, Patrick Soon-Shiong, Todd A. Fehniger
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (12): 3339–3350.
https://doi.org/10.1158/1078-0432.CCR-20-4575
Published: 15 June 2021
View article titled, Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma
Open the PDF for Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma in another window
Includes: Supplementary data
Journal Articles

First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas

Ajay K. Gopal, Ronald Levy, Roch Houot, Sandip P. Patel, Leslie Popplewell, Caron Jacobson, Xinmeng J. Mu, Shibing Deng, Keith A. Ching, Ying Chen, Craig B. Davis, Bo Huang, Kolette D. Fly, Aron Thall, Adrian Woolfson, Nancy L. Bartlett
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (11): 2524–2534.
https://doi.org/10.1158/1078-0432.CCR-19-2973
Published: 01 June 2020
View article titled, First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20<sup>+</sup> Non-Hodgkin Lymphomas
Open the PDF for First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20<sup>+</sup> Non-Hodgkin Lymphomas in another window
Includes: Supplementary data
Journal Articles

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma

Radhakrishnan Ramchandren, Ranjana H. Advani, Stephen M. Ansell, Nancy L. Bartlett, Robert Chen, Joseph M. Connors, Tatyana Feldman, Andres Forero-Torres, Jonathan W. Friedberg, Ajay K. Gopal, Leo I. Gordon, John Kuruvilla, Kerry J. Savage, Anas Younes, Gerald Engley, Thomas J. Manley, Keenan Fenton, David J. Straus
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (6): 1718–1726.
https://doi.org/10.1158/1078-0432.CCR-18-2435
Published: 15 March 2019
View article titled, Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma
Open the PDF for Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma in another window
Includes: Supplementary data
Journal Articles

A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma

Andrew M. Evens, Sriram Balasubramanian, Julie M. Vose, Wael Harb, Leo I. Gordon, Robert Langdon, Julian Sprague, Mint Sirisawad, Chitra Mani, Jeanne Yue, Ying Luan, Sharon Horton, Thorsten Graef, Nancy L. Bartlett
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (5): 1059–1066.
https://doi.org/10.1158/1078-0432.CCR-15-0624
Published: 29 February 2016
View article titled, A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma
Open the PDF for A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma in another window
Includes: Supplementary data
Journal Articles

The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas

Maximillian Rosario, Bai Liu, Lin Kong, Lynne I. Collins, Stephanie E. Schneider, Xiaoyue Chen, Kaiping Han, Emily K. Jeng, Peter R. Rhode, Jeffrey W. Leong, Timothy Schappe, Brea A. Jewell, Catherine R. Keppel, Keval Shah, Brian Hess, Rizwan Romee, David R. Piwnica-Worms, Amanda F. Cashen, Nancy L. Bartlett, Hing C. Wong, Todd A. Fehniger
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (3): 596–608.
https://doi.org/10.1158/1078-0432.CCR-15-1419
Published: 31 January 2016
View article titled, The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and <em>In Vivo</em> Clearance of B Cell Lymphomas
Open the PDF for The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and <em>In Vivo</em> Clearance of B Cell Lymphomas in another window
Includes: Supplementary data
Journal Articles

A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies

Michelle A. Fanale, Andres Forero-Torres, Joseph D. Rosenblatt, Ranjana H. Advani, Anna R. Franklin, Dana A. Kennedy, Tae H. Han, Eric L. Sievers, Nancy L. Bartlett
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (1): 248–255.
https://doi.org/10.1158/1078-0432.CCR-11-1425
Published: 02 January 2012
View article titled, A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
Open the PDF for A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies in another window
Includes: Supplementary data